Skip to main content
Fig. 2 | Orphanet Journal of Rare Diseases

Fig. 2

From: Long term substrate reduction therapy with ezetimibe alone or associated with statins in three adult patients with lysosomal acid lipase deficiency

Fig. 2

Baseline values (calculated as mean values of the 3 years preceding the start of treatment) in comparison with mean values during ezetimibe treatment and during ezetimibe and statins treatment of Alanine transaminase (ALT), Total Cholesterol (TC), LDL- Cholesterol (LDL-C), HDL Cholesterol (HDL-C), Triglycerides (TG). In order to make data comparable, values are expressed as a ratio with maximum or minimal normal values for age according to our laboratory. ALT reference 10-45 IU/L; Total Cholesterol (TC) reference value below 5.17 mmol/L, Triglycerides (TG) reference value 0.3–1.7 mmol/L, HDL cholesterol (HDL-C) reference value above 1.16 mmmol/L, LDL cholesterol (LDL-C) reference value below 3.36 mmol/L. E10 = ezetimibe 10 mg/day; A10 = atorvastatin 10 mg/day

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172